

"BIOMED- LUBLIN" Serum and Vaccine Production Plant JSC

10 Uniwersytecka Str. 20-029 Lublin, Poland



History

- 1944- Establishing of Biomed Lublin Serum and Vaccine Production Plant. Fromthat moment on the objective of the comapny's unchanging quality policy is patient care and wellbing as well as our country's health problems. From the very beginning of its existence Biomed Lublin greatly contributes in battling our country's most significant health problems – from the production of vaccines against typhoid, rabies, dysentery and Polio during its earlier years to the present production of tuberculosis vaccine.
- 2001- Biomed's transformation into Biomed Lublin Ltd.
- 2010- Biomed's transformation into "BIOMED- LUBLIN" JSC. BIOMED comes onto Stock Exchange.



Basic production covers:

- bacterial preparations
- Anti- Tuberculosis Vaccine BCG 10
- blood-derivated preparations
- enzymatic preparations
- suppository preparations

Other products include diagnostic preparations, used in biochemical and medical laboratories.





The company's annual turnover in 2017 was 31 271 168 PLN, of which export was 11 241 057 PLN.


We have registered and sold Distreptaza to the following countries: Ukraine, Belarus, Azerbaijan, Georgia, Mongolia, Moldova, Kazakhstan, Kyrgyzstan, Tajikistan, Uzbekistan.

The BCG vaccine we have registered in Ukraine and in Uzbekistan. We sell to: Ukraine, Latvia, Croatia, France, Hungary, Slovenia, Czech Republic, Australia, Bosnia and Herzegovina.

Onko BCG we have registered in Uruguay and Ukraine. We sell to the following countries: Uruguay, Hungary, Bosnia and Herzegovina, Republika Srpska, Montenegro, Kosovo, Kuwait, United Arab Emirates, Turkey.




Value Euro





Value PLN





DISTREPTAZA®

(Streptokinasum+Streptodornasum)

Suppositories 15,000 i.u. + 1250 i.u.

ATC: B 06 AA 55





Indications for use:

Chronic adnexitis, intumescences, post-operative changes, uterus mucous membrane inflammation, acute and chronic haemorrhoids, rectal abscesses, fistulas with excessive inflammatory intumenscences. Purulent pericaudal cysts.



Onko BCG® 100

(Vaccinum BCG)

ATC: L 03 AX 03

Powder for preparation of suspended matter to be applied to bladder



Ampoule contains lyophilisated suspension of live, attenuated BCG, Brazilian Moreau sub-strain, dried in high vacuum from frozen.

Indications for use:

The medicine is intended for treatment of superficial, non-invasive tumours (carcinoma urotheliae Ta, Tis, T1).



Onko BCG® 50,

(Vaccinum BCG)

ATC: L 03 AX 03

Powder for preparation of suspended matter to be applied to bladder



Indications for use:

The medicine is intended for treatment of superficial, non-invasive tumours (carcinoma urotheliae Ta, Tis, T1). The preparation in 50mg dose may be used in case of repetitive side effects (dysuria, high temperature) or acute tuberculin reaction.



BCG 10 Anti-Tuberculosis Vaccine

(Vaccinum BCG antituberculosum)

ATC: J 07 01



10-dose vaccine. Powder and solvent for preparation of suspended matter for intracutaneous injections. Ampoule with powder contains:BCG mycobacteria, Moreau sub-strain.

Indications for use:

Anti-tuberculosis BCG vaccine is intended for immunization against tuberculosis.



GAMMA anti-HBs 200

(Immunoglobulinum humanum hepatitis B)
ATC: J 06 BB 04
Solution for intramuscular injections 200 i.u.



Indications for use:

Passive prophylactics of type B hepatitis. Product intended for use in infants, whose mothers underwent type B hepatitis during pregnancy, or are antygen HBs carriers, as well as for children whose body mass up to 50 kg, especially susceptible to hospital HBV infection.



GAMMA anti-HBs 1000

(Immunoglobulinum humanum hepatitis B) ATC: J 06 BB 04

Solution for intramuscular injections 1000 i.u.



Indications for use:

Passive prophylactics of type B hepatitis.

Product intended for use in:

- Adult and children, not vaccinated against type B hepatitis, especially susceptible to hospital HBV infection
- Medical personel, not vaccinated against type B hepatitis, after exposure to HBV: pricking with needle, cutting, wound impurity or through mucous membranes
- Sexual partners of people suffering from acute type B hepatitis





GAMMA Anti-D 50

(Solution for intramuscular injections, 50 μg.)

Immunoglobulinum humanum anti-D

ATC: J 06 BB 01

Solution for intramuscular injections, 50µg.

Indications for use:

Generally- serologic incompatibiliti. Product intended for use after spontaneous abortion, artificial abortion or ectopic pregnancy abortion. Product to be applied to Rh negative women without anti-D antibodies in serum.





GAMMA AntiD 150

(Solution for intramuscular injections, 150 μg.)

Immunoglobulinum humanum anti-D

ATC: J 06 BB 01

Solution for intramuscular injections, 150µg.

Indications for use:

Generally- serologic incompatibiliti.

- Mother is Rh negative (D-). Anti-D antibodiesare not present in the mother's serum. Baby is Rh positive (D+). Direct anti-globulin test in baby yields, negative result.
- Product is applied during pregnancy. Ror those Rh negative women in which no anti-D antibodies have been discovered using papain test and anti-globulinapplication in 28 week of pregnancy.
- Product is intended to be applied after foetus removal later than in 12 week, in case of imminent immature or premature delivery, after diagnostic amniopuncture later than in 12 week to women with no anti-D antibodies discovered.



BioTrombina® 400

(Thrombinum)
ATC: B 02 BC 06
Lyophilisate and solvent for preparation of solution for local application.



Indications for use:

Local suppression of intensive bleeding in surgery from internal organs such as liver, kidneys, lungs, in dental surgery - in tooth socket bleedings after tooth extraction, in laryngology - in bleedings from nose, mouth mucosa, after Tonsil removal, in gynaecology.



MEDICAL DEVICES & REAGENTS



- •MZ-LATEKS
- STAPHYLOCOCCUS AUREUS TEST
- OX THROMBIN
- RABBIT COMPLEMENT
- RABBIT PLASMA
- LYOPHILISATE COMPLEMENT
- OX FIBRYNOGEN
- PSEUDOCHOLINESTERASE
- · LÖWENSTEIN-JENSEN MEDIA
- STONEBRINK MEDIUM









- OGAWA MEDIUM
- RPMI 1640 MEDIUM
- EAGLE 1959 MEDIUM
- DULBECCO'S MEDIUM
- PARKER'S MEDIUM
- HANKS' MEDIUM
- PBS FLUID
- TRYPSIN
- CALF SERUM
- BOVINE SERUM
- HORSE SERUM
- RAM BLOOD





















CONTACTS

Alexander Tsymbal

Global Product Manager

BIOMED-LUBLIN WSiSz. S.A.

www.biomedlublin.com

20-029 Lublin, Poland,

ul. Uniwersytecka, 10

tel.: + 48 81 533 82 21

mob: +48 668 886 530

WhatsApp: +38 050 315 92 01

email: atsymbal@biomedlublin.com